Semaglutide is the compound whose dosing chart most people have already seen, because the Wegovy label prints one. What the label does not print is a figure in syringe units, since every approved product is a pen or a tablet. That gap is where the dosing errors the FDA reported in 2024 happened, and it is the gap this page works: the label and trial schedules first, each with its date, then the same milligram figures as units at the concentrations a 5 mg or 10 mg vial can produce.
Semaglutide is a GLP-1 receptor agonist sold by Novo Nordisk as Wegovy (weight reduction, cardiovascular risk reduction and MASH) and Ozempic (type 2 diabetes), as weekly injections and, since the 2026 labels, as daily tablets. Medibact's Semaglutide guide covers the molecule and its evidence; this page stays with figures. The dosage hub lists every compound.
What the sources state
| Source | Kind | Figure | Date read |
|---|---|---|---|
| Wegovy label, Novo Nordisk (revised 6/2026; DailyMed version published 2026-06-30) | Approved label | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1 mg weeks 9 to 12, 1.7 mg weeks 13 to 16; maintenance 2.4 mg (recommended) or 1.7 mg once weekly; 7.2 mg once weekly possible after at least 4 weeks tolerated at 2.4 mg | 2026-09-18 |
| Wegovy label, tablets | Approved label | 1.5 mg days 1 to 30, 4 mg days 31 to 60, 9 mg days 61 to 90, then 25 mg once daily | 2026-09-18 |
| Ozempic label, Novo Nordisk (revised 5/2026; DailyMed version published 2026-06-10) | Approved label | 0.25 mg once weekly for 4 weeks, then 0.5 mg; 1 mg and 2 mg after at least 4 weeks on each; maximum 2 mg once weekly | 2026-09-18 |
| STEP 1, NCT03548935 (1,961 participants; results posted 2021-08-11) | Trial protocol | 0.25, 0.5, 1.0, 1.7 mg in four-week steps, 2.4 mg from week 17 to 68 | 2026-09-18 |
| Wilding et al., NEJM 2021 (PMID 33567185) | Trial publication | -14.9% body weight at week 68 vs -2.4% placebo | 2026-09-18 |
| Wharton et al., Lancet Diabetes Endocrinol 2025 (PMID 40961952), STEP UP | Trial publication | 7.2 mg -18.7%, 2.4 mg -15.6%, placebo -3.9% at 72 weeks; 1,407 participants | 2026-09-18 |
| FDA MedWatch bulletin, 2024-07-29 | Regulator alert | Compounded-vial dosing errors of five to twenty times the intended dose from unit confusion; adverse events listed | 2026-09-18 |
| Pharmacy, clinic and calculator pages | Commonly cited | Compounded concentrations of 2.5 to 10 mg/mL; a 5 mg/mL chart with 0.25 mg = 5 units | 2026-09-18 |
The label schedule is the STEP 1 schedule with one step added from STEP UP. The 7.2 mg strength was approved on 2026-03-19, and the June 2026 Wegovy label is the first to carry it alongside the tablet.
The strengths on the labels
Every approved injection states its concentration, which is why a pen dose needs no arithmetic. Wegovy single-dose pens hold 0.25, 0.5 or 1 mg in 0.5 mL, and 1.7, 2.4 or 7.2 mg in 0.75 mL; the multi-dose FlexTouch holds 9.6 mg in 3 mL, or 3.2 mg/mL. Ozempic pens hold 2 mg, 4 mg or 8 mg in 3 mL, which is 0.68, 1.34 and 2.68 mg/mL. A DailyMed search for semaglutide on 2026-09-18 returned nine records, all Novo Nordisk products or repackagings of them; no approved powder vial exists.
Units per dose at each research-vial size
Research-market semaglutide is supplied in 5 mg and 10 mg vials. The table takes each at 1, 2 and 3 mL of water, gives the concentration, and converts the label steps into U-100 syringe units (100 units = 1 mL). A cell over 100 units does not fit one syringe at that concentration.
| Vial | Water added | Concentration | 250 mcg | 500 mcg | 1 mg | 1.7 mg | 2 mg | 2.4 mg | 7.2 mg |
|---|---|---|---|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 5 | 10 | 20 | 34 | 40 | 48 | 144 (>1 syringe) |
| 5 mg | 2 mL | 2.5 mg/mL | 10 | 20 | 40 | 68 | 80 | 96 | 288 (>1 syringe) |
| 5 mg | 3 mL | 1.67 mg/mL | 15 | 30 | 60 | 102 (>1 syringe) | 120 (>1 syringe) | 144 (>1 syringe) | 432 (>1 syringe) |
| 10 mg | 1 mL | 10 mg/mL | 2.5 | 5 | 10 | 17 | 20 | 24 | 72 |
| 10 mg | 2 mL | 5 mg/mL | 5 | 10 | 20 | 34 | 40 | 48 | 144 (>1 syringe) |
| 10 mg | 3 mL | 3.33 mg/mL | 7.5 | 15 | 30 | 51 | 60 | 72 | 216 (>1 syringe) |
The first row is the 5 mg/mL chart that circulates most widely, and it holds only for a vial at exactly that concentration. The 10 mg/mL row shows the other side of the same arithmetic: at that strength the first label step is 2.5 units, a quarter of a millimetre on most syringe scales, which is the measurement problem the smaller-barrel syringes exist to solve. The semaglutide calculator works any vial, water volume and amount entered, and the semaglutide reconstitution page covers the water volumes per vial size in full.
What the FDA's 2024 bulletin recorded
The MedWatch bulletin of 2024-07-29 is the one regulator document that speaks directly to the units question. It reported patients who had been instructed to draw a small dose, such as 5 units (0.05 mL), from a multi-dose vial and instead administered 50 units, and more generally patients drawing five to twenty times the intended dose. The FDA attributed the errors to unfamiliarity with drawing from a vial and to confusion between millilitres, milligrams and units, noted that compounded products come in different concentrations, and asked prescribers to provide a syringe sized to the intended dose. The adverse events listed were gastrointestinal effects, fainting, headache, migraine, dehydration, acute pancreatitis and gallstones, with some patients hospitalised. That is the concrete reason a unit figure on this page is never printed without its concentration.
What the figures omit
The labels attach a weekly interval, four-week holds at each step, an indication and an approved concentration to every figure, and the tablet attaches 30-day steps and daily dosing. STEP 1 and STEP UP attach durations of 68 and 72 weeks and populations selected by BMI. A research vial attaches nothing until water is added, and the arithmetic above moves the milligram figures across without their conditions. Nothing in any label describes reconstituting a powder, because no approved product is one.
Related pages
Tirzepatide dosage reports the other labelled incretin on this site, retatrutide dosage the one without a label, and cagrilintide dosage the amylin analogue studied alongside semaglutide as CagriSema. The general mixing procedure is documented on medibact.com's how to reconstitute peptides page; the reconstitution chart on this site lists concentrations for every vial size.
The insulin syringe units how-to explains the U-100 and U-40 scales and how a milligram figure becomes a syringe reading.
What this page does not do
This page reports what the two labels, two trials, one FDA bulletin and the public web state about semaglutide dosing, each with its source and date, and converts the sourced figures into syringe units at the concentrations a 5 mg or 10 mg vial can produce. It does not recommend an amount, a concentration, a step or a schedule. The label schedule is reported as the label states it, for the products the label covers, and the tables are arithmetic, not a plan.
Sources and dates
Opened 2026-09-18: the Wegovy label on DailyMed (set id ee06186f-2aa3-4990-a760-757579d8f77b, revised 6/2026) and the Ozempic label on DailyMed (set id adec4fd2-6858-4c99-91d4-531f5f2a2d79, revised 5/2026); the DailyMed SPL search for semaglutide (nine records); NCT03548935 on ClinicalTrials.gov; PMID 33567185 (Wilding et al., NEJM 2021) and PMID 40961952 (Wharton et al., Lancet Diabetes Endocrinol 2025); the FDA MedWatch bulletin of 2024-07-29 on compounded injectable semaglutide dosing errors; and a read of pharmacy, clinic and calculator pages for the compounded concentrations in circulation. Corrections go to the contact page.